Aditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801
The Fly

Aditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801

Aditxt (ADTX) shared a milestone for its target acquisition, Appili Therapeutics (APLIF), announcing that the FDA has provided “positive” feedback regarding the development strategy for ATI-1801.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App